ETODOLAC 200 MG — DIN 02232317
ETODOLAC : 200 MG · AA PHARMA INC · CAPSULE · wholesale supply in Canada
Health Canada status: DORMANT
What is ETODOLAC?
ETODOLAC 200 MG contains ETODOLAC : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02232317, held by AA PHARMA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as dormant, status dated 10-Dec-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How much does Etodolac cost around the world?
Etodolac is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Saudi Arabia publishes a public; United States publishes a acquisition. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 22 | USD███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
23 pack listings across 5 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Etodolac pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Etodolac in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Etodolac, across 12 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 2 | 0 | ETODOLAC | No marketed DIN |
| APOTEX INC | 2 | 0 | ETODOLAC | No marketed DIN |
| GENPHARM ULC | 2 | 0 | GEN-ETODOLAC 200MG, GEN-ETODOLAC 300MG | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | NOVO-ETODOLAC 200 MG, NOVO-ETODOLAC 300 MG | No marketed DIN |
| PROCTER & GAMBLE PHARMACEUTICALS CANADA INC | 2 | 0 | ULTRADOL - CAP 200MG, ULTRADOL - CAP 300MG | No marketed DIN |
| TARO PHARMACEUTICALS INC | 2 | 0 | TARO-ETODOLAC, TARO-ETODOLAC 200 MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Etodolac |
|---|---|
| ATC code | M01AB08 |
| AHFS class | 28:08.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02232317 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2232317 |
| Brand name | ETODOLAC |
| Generic / active ingredient | ETODOLAC : 200 MG |
| Market authorization holder | AA PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | M01AB08 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01AB |
| Current status | DORMANT |
| Status date | 10-Dec-2021 |
| Original market date | 1997-08-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ETODOLAC | 300 MG | CAPSULE | APOTEX INC | APPROVED | 02231967 |
| ETODOLAC | 200 MG | CAPSULE | APOTEX INC | APPROVED | 02231965 |
| ETODOLAC | 300 MG | CAPSULE | AA PHARMA INC | DORMANT | 02232318 |
| GEN-ETODOLAC 200MG | 200 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | 02239319 |
| GEN-ETODOLAC 300MG | 300 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | 02239320 |
| NOVO-ETODOLAC 200 MG | 200 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED PRE MARKET | 02242205 |
| NOVO-ETODOLAC 300 MG | 300 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED PRE MARKET | 02242206 |
| TARO-ETODOLAC | 300 MG | CAPSULE | TARO PHARMACEUTICALS INC | CANCELLED POST MARKET | 02242915 |
| TARO-ETODOLAC 200 MG | 200 MG | CAPSULE | TARO PHARMACEUTICALS INC | CANCELLED POST MARKET | 02242914 |
| ULTRADOL - CAP 200MG | 200 MG | CAPSULE | PROCTER & GAMBLE PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02142023 |
2 · Same class — other molecules in ATC M01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diclofenac | APO-DICLO · APO-DICLO RAPIDE 50 MG TABLETS · APO-DICLO SR · AVA-DICLOFENAC · +44 more | 74 | 15 | Yes |
| Ketorolac | APO-KETOROLAC · APO-KETOROLAC INJECTABLE · JAMP KETOROLAC · KETOROLAC TROMETHAMINE INJECTION USP · +12 more | 25 | 8 | Yes |
| Indometacin | APO-INDOMETHACIN · AURO-INDOMETHACIN · FTP-INDOMETHACIN · INDOCID CAP 25MG · +18 more | 31 | 7 | Yes |
| Diclofenac, Combinations | ACT DICLO-MISO · ARTHROTEC 50 · ARTHROTEC 75 · DICLOFENAC MISOPROSTOL · +4 more | 12 | 6 | Yes |
| Sulindac | APO-SULIN TAB 150MG · APO-SULIN TAB 200MG · CLINORIL TAB 150MG · CLINORIL TAB 200MG · +6 more | 12 | 2 | Yes |
| Etodolac | ETODOLAC · GEN-ETODOLAC 200MG · GEN-ETODOLAC 300MG · NOVO-ETODOLAC 200 MG · +5 more | 12 | 0 | Not in Canada |
| Tolmetin | NOVO-TOLMETIN CAPSULES 400MG · TOLECTIN 200 TAB 200MG · TOLECTIN 400 CAP 400MG · TOLECTIN TAB 600MG | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M01AE | Fenoprofen · Flurbiprofen · Ibuprofen · Ibuprofen, Combinations · Ketoprofen · +5 more | 398 | 101 |
| M01AH | Celecoxib · Rofecoxib | 72 | 30 |
| M01AC | Meloxicam · Piroxicam · Tenoxicam | 67 | 14 |
| M01AG | Mefenamic Acid | 7 | 1 |
| M01AX | Nabumetone | 12 | 1 |
| M01AA | Oxyphenbutazone · Phenylbutazone · Phenylbutazone, Combinations | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.